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Obesity is a major health problem faced 
by many countries including low-middle 
income country (LMIC). In 2016, 39% of adults 
aged 18 years and over were overweight, and 
13% were obese (11% men and 15% women). 
Both overweight and obesity have shown a 
marked increase over the last four decades. The 
worldwide prevalence of obesity nearly tripled 
between 1975 and 2016.(1) On the basis of these 
data, the author agrees with Gammone(2) who 
categorizes obesity as a pandemic, in contrast to 
Dian in the currently published article, that 
obesity is an epidemic. Dian has discussed in 
detail the relationship between obesity as a 
high-risk factor for COVID-19 mortality and its 
management. 
It is well known that obesity is 
associated with other health problems, 
including hypertension, high cholesterol, 
diabetes, cardiovascular disease, respiratory 
problems, musculoskeletal disease (arthritis) 
and some forms of cancer.(1,3) Obesity is closely 
related to metabolic syndrome (MetS). MetS is 
a cluster of abnormalities that includes 
diabetes mellitus (DM), morbid obesity, 
dyslipidaemia, and hypertension which are risk 
factors for developing cardiovascular disease 
(CVD) and chronic kidney disease (CKD).(4) The 
prevalence of MetS on average is 31%, and 
associated with a two-fold increase in the risk 
of coronary heart disease, cerebrovascular 
disease, and a 1.5-fold increase in the risk of all-
cause mortality.(5) 
Furthermore, based on available data, 
obesity was found to be associated with a 
higher risk of developing severe pneumonia 
and death among COVID-19 patients.(6) Even 
obese COVID-19 patients were also associated 
with a higher prevalence of long-Covid-19 
compared to non-obese COVID-19 patients.(7) 
Patients with metabolic syndrome were nearly 
five times more likely to require intensive care 
and a ventilator or to experience respiratory 
distress and 3.4 times more likely to die from 
infection.(8)Compared with patients with 
normal body mass indexes (BMI), the risk of 
hospital admission was 28% and 30% higher in 
patients with moderate and severe obesity, 
respectively.(9) Other data also show that 
Samsu Nur  CRJIM2(2): November 2021 
 
 CRJIM • Vol 02• Number 2 • November 2021  Page | 164 
obesity and diabetes are associated with an 
increased likelihood of hospitalization, 
requiring intensive care and ventilation.(8,10) 
Obesity is linked to Poor COVID-19 Outcomes 
Obesity is associated with impaired 
ability to fight infection, including SAR-CoV-2 
infection and is believed to be a major risk 
factor for the development of severe COVID-19 
infection and mortality.(9) Results from a 
systematic review and meta-analysis of 75 
studies on obesity and COVID-19 found that 
obese people were 1.5 times more likely to be 
infected with the coronavirus than their non-
obese counterparts, 2.1 times more likely to be 
hospitalized because of their infection, were 1.7 
times more likely to be admitted to the ICU, and 
1.5 times more likely to die from the virus.(10)  
Patients aged under 60 yearsold with a BMI of 
30–34 kg/m2 were two and 1.8 times more likely 
to be admitted to acute and critical care, 
respectively, compared with individuals with 
BMI 30 kg/m2, with the risk escalating for BMI 35 
kg/m2 (2.2 and 3.6 times, respectively).(11) 
The exact mechanism by which obese 
people increase the risk of developing severe 
manifestations of COVID-19 is not yet known. 
However, there are several potential 
mechanisms, such as chronic systemic 
phlogistic states, dysfunctional and delayed 
immune responses, and even adipose tissue 
itself.(2) Metabolic derangement and chronic 
inflammation of the adipose tissue depots 
leading to blunted macrophage activation and 
impaired T and B lymphocyte responses.(12) 
• Adipose tissue as a reservoir for SARS-
CoV-2 that increases viral load. This is 
because the level of ACE2 expression in 
adipose tissue is higher than that in lung 
tissue, so obese individuals (with more 
adipose tissue), produce greater 
amounts of ACE2.(13) 
• Obesity is also characterized by 
increased activation of the systemic and 
local adipose tissue renin-angiotensin 
system, thus ACE2 in adipose tissue may 
be closely related to susceptibility to 
COVID-19, which results in poor 
outcomes for obese patients.(14) 
• Adipose tissue represents an 
independent endocrine organ. It releases 
a great number of bioactive peptides, 
collectively named “adipokines,” which 
play a central role in both immunity and 
vascular homeostasis.(2) 
• Adipose tissue is also a source of many 
pro-inflammatory mediators and 
hormones, which regulate a low-grade 
inflammation and hypercoagulable 
states.(2) 
There were high baseline serum levels 
of C reactive protein (CRP) and interleukin 6 (IL-
6), as well as hypoadiponectinemia and 
hyperleptinemia/leptin resistance (typical of 
obesity).(2) Above conditions explains the pre-
existing inflammatory microenvironment in 
obese patients, making them more susceptible 
to worse outcomes and even death. Both 
excess adipose accumulation and loss of lean 
mass can affect entire body function. These 
changes may impair not only the 
immunological response to the virus, but also 
inflammatory reactions, respiratory and 
metabolic disturbances. In addition, in the long 
term, can be the length of time required for 
recovery, long-term risks, and acquired 
weakness in the intensive care unit, which 
globally increase the risk of critical illness and 
death.(2) 
Obesity as a Risk Factor for Long- COVID 
Long-COVID has been defined as the 
persistence of symptoms, or the development 
of new symptoms, relating to SARS-CoV-2 
infection late in the course of COVID-19, at least 
Samsu Nur  CRJIM2(2): November 2021 
 
 CRJIM • Vol 02• Number 2 • November 2021  Page | 165 
28 days after diagnosis. Symptom frequency 
could be constant or fluctuate, and it may 
involve other systems.(15) Emerging data 
indicate that some COVID-19 survivors 
experience symptoms beyond the usual 
recovery time of SARS-CoV-2 infection. These 
symptoms and problems, collectively called 
the postacute sequelae of COVID-19 (PASC), can 
range from mild to disabling severity and can 
affect different body organs and systems.(16) 
As described above, obese patients are 
at risk for long-term disabilities.(2,16) Based on 
the study results, it has been proven that 
obesity affects clinical manifestations, immune 
function and endocrine metabolism in patients 
discharged after recovering from COVID-19.(6)  
However, the specific mechanism by which 
obesity leads to residual symptoms after 
discharge and abnormal laboratory results is 
still unclear.(7) The factors associated with this 
risk may be related to problems associated with 
obesity itself, which is a proinflammatory and 
pro-thrombotic disease condition, which has 
higher inflammatory cytokines than nonobese 
individuals. Several factors that may underlie 
the long-term effects of obesity on hospital 
discharge COVID-19 patients are as follows: 
• Increased inflammatory response 
caused by excessive cytokine release, 
resulting in oxidative stress that results in 
abnormal liver function, elevated uric 
acid levels, and higher lipids in obese 
patients than in non-obese patients.(7) 
• Changes in eating habits and lack of 
physical activity during the pandemic, 
which can cause metabolic disorders in 
COVID-19 patients after being 
discharged.(16) 
• Obesity is known to be associated with 
decreased lung function and adverse 
reactions to mechanical ventilation.(17) 
• Physiologically, increased body weight is 
associated with decreased functional 
residual capacity (FRC) and decreased 
expiratory reserve, which restricts 
expiratory flow and induces airway 
closure, thereby decreasing lung 
diffusion capacity in obese individuals.(18) 
• Pre-existing medical conditions (e.g 
hypertension, hyperlipidemia, diabetes), 
which are known to be closely related to 
obesity.  
• The effect of certain drugs that were 
routinely consumed previously related to 
the problem of increasing BMI.  
• Vaccines are known to be less effective in 
obese people than non-obese.(2) 
• Dietary problems and activity restrictions 
associated with COVID-19 that can 
exacerbate obesity in individuals 
Finally, it is clear that obesity is a major 
health challenge due to its high and rapidly 
increasing prevalence and is associated with an 
increased risk of various diseases that 
contribute to decreased quality of life and life 
expectancy. Reducing the burden of obesity 
requires an approach that combines individual 
interventions with environmental and social 
changes, including government policies on 
strict regulation of information warning labels 
on packaged foods high in sugar, fat, and salt, 
and limiting the marketing of unhealthy foods, 
especially to children. In light of the COVID-19 
pandemic, it has been shown that obesity is 
associated with an increased incidence of 
mortality and morbidity and a higher 
prevalence of long-COVID than non-obese 
COVID-19 patients. By having a higher adverse 
outcome, individuals with higher BMI are 
potentially classified as high risk and, 
therefore, prioritized for COVID-19 testing and 
closer management and monitoring. 
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